Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does DAPAGLIFLOZIN PROPANEDIOL Cause Gait inability? 28 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 28 reports of Gait inability have been filed in association with DAPAGLIFLOZIN PROPANEDIOL (FARXIGA). This represents 0.2% of all adverse event reports for DAPAGLIFLOZIN PROPANEDIOL.

28
Reports of Gait inability with DAPAGLIFLOZIN PROPANEDIOL
0.2%
of all DAPAGLIFLOZIN PROPANEDIOL reports
0
Deaths
6
Hospitalizations

How Dangerous Is Gait inability From DAPAGLIFLOZIN PROPANEDIOL?

Of the 28 reports, 6 (21.4%) required hospitalization.

Is Gait inability Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for DAPAGLIFLOZIN PROPANEDIOL. However, 28 reports have been filed with the FAERS database.

What Other Side Effects Does DAPAGLIFLOZIN PROPANEDIOL Cause?

Death (3,443) Fungal infection (1,204) Blood glucose increased (778) Weight decreased (777) Urinary tract infection (583) Dizziness (582) Diabetic ketoacidosis (547) Nausea (460) Fatigue (442) Pollakiuria (388)

What Other Drugs Cause Gait inability?

ADALIMUMAB (3,844) ETANERCEPT (2,710) METHOTREXATE (2,559) TOFACITINIB (2,227) SECUKINUMAB (2,216) TOCILIZUMAB (2,139) LEFLUNOMIDE (2,065) RITUXIMAB (2,028) ABATACEPT (2,019) HYDROXYCHLOROQUINE (1,881)

Which DAPAGLIFLOZIN PROPANEDIOL Alternatives Have Lower Gait inability Risk?

DAPAGLIFLOZIN PROPANEDIOL vs DAPAGLIFLOZIN PROPANEDIOL\METFORMIN DAPAGLIFLOZIN PROPANEDIOL vs DAPRODUSTAT DAPAGLIFLOZIN PROPANEDIOL vs DAPSONE DAPAGLIFLOZIN PROPANEDIOL vs DAPTOMYCIN DAPAGLIFLOZIN PROPANEDIOL vs DARATUMUMAB

Related Pages

DAPAGLIFLOZIN PROPANEDIOL Full Profile All Gait inability Reports All Drugs Causing Gait inability DAPAGLIFLOZIN PROPANEDIOL Demographics